Arjuna Capital Buys 1,537 Shares of McKesson Corporation $MCK

Arjuna Capital boosted its holdings in shares of McKesson Corporation (NYSE:MCK) by 40.5% in the fourth quarter, Holdings Channel.com reports. The fund owned 5,334 shares of the company’s stock after acquiring an additional 1,537 shares during the quarter. McKesson comprises 1.1% of Arjuna Capital’s portfolio, making the stock its 20th biggest holding. Arjuna Capital’s holdings in McKesson were worth $4,375,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of MCK. J.W. Cole Advisors Inc. lifted its holdings in shares of McKesson by 35.3% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock worth $3,931,000 after buying an additional 1,329 shares during the period. Cullen Investment Group LTD. lifted its holdings in shares of McKesson by 550.4% in the 4th quarter. Cullen Investment Group LTD. now owns 4,670 shares of the company’s stock worth $3,811,000 after buying an additional 3,952 shares during the period. Private Wealth Partners LLC lifted its holdings in shares of McKesson by 5.6% in the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after buying an additional 1,682 shares during the period. AlphaQuest LLC lifted its holdings in shares of McKesson by 91.2% in the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock worth $1,365,000 after buying an additional 843 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of McKesson by 12.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after buying an additional 36,451 shares during the period. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on MCK. Mizuho upped their target price on McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. Weiss Ratings reaffirmed a “buy (b+)” rating on shares of McKesson in a research report on Monday, May 4th. UBS Group upped their target price on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Raymond James Financial set a $970.00 target price on McKesson in a research report on Thursday, March 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $875.00 target price on shares of McKesson in a research report on Friday, May 8th. Fourteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, McKesson presently has an average rating of “Moderate Buy” and an average price target of $968.87.

Insiders Place Their Bets

In other McKesson news, EVP Leann B. Smith sold 190 shares of the stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $945.00, for a total transaction of $179,550.00. Following the transaction, the executive vice president owned 2,989 shares in the company, valued at approximately $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Maria Martinez sold 349 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total value of $328,014.63. Following the transaction, the director owned 301 shares in the company, valued at $282,900.87. This represents a 53.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,264 shares of company stock worth $3,205,315. 0.08% of the stock is owned by corporate insiders.

McKesson Stock Up 1.7%

McKesson stock opened at $759.82 on Friday. The firm has a market cap of $91.33 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.11 and a beta of 0.35. The business’s 50-day moving average price is $854.83 and its 200 day moving average price is $857.22. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. The company had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.McKesson’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts expect that McKesson Corporation will post 44.29 EPS for the current year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is currently 8.53%.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.